TWI662024B - 雜芳基化合物及其用途 - Google Patents
雜芳基化合物及其用途 Download PDFInfo
- Publication number
- TWI662024B TWI662024B TW104101242A TW104101242A TWI662024B TW I662024 B TWI662024 B TW I662024B TW 104101242 A TW104101242 A TW 104101242A TW 104101242 A TW104101242 A TW 104101242A TW I662024 B TWI662024 B TW I662024B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- Prior art date
Links
- 0 CC(Nc1cc(-c2cnc(*s([n]3)(N4CCCC4)=O)c3c2C)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(*s([n]3)(N4CCCC4)=O)c3c2C)ccn1)=O 0.000 description 2
- WYRMOJUSNQZIAP-UHFFFAOYSA-N CC(C)(C)NS(c1c(C)c(-c2cc(NC(C)=O)ncc2)cnc1N(C)C)(=O)=O Chemical compound CC(C)(C)NS(c1c(C)c(-c2cc(NC(C)=O)ncc2)cnc1N(C)C)(=O)=O WYRMOJUSNQZIAP-UHFFFAOYSA-N 0.000 description 1
- UWHKLTDYHWSOHZ-UHFFFAOYSA-N CC(CCCC1)N1c1cc(-c2ccnc(NC(C)=O)c2)cnc1C#N Chemical compound CC(CCCC1)N1c1cc(-c2ccnc(NC(C)=O)c2)cnc1C#N UWHKLTDYHWSOHZ-UHFFFAOYSA-N 0.000 description 1
- VSEUFVWZHDLOGT-UHFFFAOYSA-N CC(Nc1cc(-c(c(C)c2NS(c3c[n](C)nc3C(F)(F)F)(=O)=O)cnc2Cl)ccn1)=O Chemical compound CC(Nc1cc(-c(c(C)c2NS(c3c[n](C)nc3C(F)(F)F)(=O)=O)cnc2Cl)ccn1)=O VSEUFVWZHDLOGT-UHFFFAOYSA-N 0.000 description 1
- FXAZTYJJMQHRFP-UHFFFAOYSA-N CC(Nc1cc(-c(cc2N(CCCN3)S3(=O)=O)cnc2N)ccn1)=O Chemical compound CC(Nc1cc(-c(cc2N(CCCN3)S3(=O)=O)cnc2N)ccn1)=O FXAZTYJJMQHRFP-UHFFFAOYSA-N 0.000 description 1
- ARIPSOPFFACZTI-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(C(N(C)c(ccc(F)c3)c3F)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(C(N(C)c(ccc(F)c3)c3F)=O)c2)ccn1)=O ARIPSOPFFACZTI-UHFFFAOYSA-N 0.000 description 1
- CPGJJXBAAFDRML-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(N(CCCN3)S3(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(N(CCCN3)S3(=O)=O)c2)ccn1)=O CPGJJXBAAFDRML-UHFFFAOYSA-N 0.000 description 1
- JUCOWKNDGXKVJJ-UHFFFAOYSA-N CC(Nc1cc(-c2cnc(C)c(N(CCN3C)S3(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cnc(C)c(N(CCN3C)S3(=O)=O)c2)ccn1)=O JUCOWKNDGXKVJJ-UHFFFAOYSA-N 0.000 description 1
- BZCNQOANJOIXBP-UHFFFAOYSA-N CC(Nc1cc(-c2cncc(N(CCO)S(c(c(F)c3)ccc3F)(=O)=O)c2)ccn1)=O Chemical compound CC(Nc1cc(-c2cncc(N(CCO)S(c(c(F)c3)ccc3F)(=O)=O)c2)ccn1)=O BZCNQOANJOIXBP-UHFFFAOYSA-N 0.000 description 1
- QJAJNEWXKJKBJH-UHFFFAOYSA-N CC(Nc1nccc(-c(cc2S(Nc(ccc(F)c3)c3F)(=O)=O)cnc2N(C)C)c1)=O Chemical compound CC(Nc1nccc(-c(cc2S(Nc(ccc(F)c3)c3F)(=O)=O)cnc2N(C)C)c1)=O QJAJNEWXKJKBJH-UHFFFAOYSA-N 0.000 description 1
- NXEAMZULBMRWDK-UHFFFAOYSA-N CC(Nc1nccc(-c(cn2)cc3c2OCCNS3(=O)=O)c1)=O Chemical compound CC(Nc1nccc(-c(cn2)cc3c2OCCNS3(=O)=O)c1)=O NXEAMZULBMRWDK-UHFFFAOYSA-N 0.000 description 1
- JWRFEEOAZCFRBM-UHFFFAOYSA-N CCOC(Nc1cc(-c(c(C)c2NS(c(c(F)c3)ccc3F)(=O)=O)cnc2Cl)ccn1)=O Chemical compound CCOC(Nc1cc(-c(c(C)c2NS(c(c(F)c3)ccc3F)(=O)=O)cnc2Cl)ccn1)=O JWRFEEOAZCFRBM-UHFFFAOYSA-N 0.000 description 1
- RJXWZHZKZNKSEQ-UHFFFAOYSA-N CCOC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)c1)=O Chemical compound CCOC(Nc1nccc(-c2cnc(C)c(NS(c(ccc(F)c3)c3F)(=O)=O)c2)c1)=O RJXWZHZKZNKSEQ-UHFFFAOYSA-N 0.000 description 1
- PIVHURGZHDITTH-UHFFFAOYSA-N Cc(c(-c1cc(Nc2nc(C)ncc2)ncc1)cnc1Cl)c1NS(N(C)C)(=O)=O Chemical compound Cc(c(-c1cc(Nc2nc(C)ncc2)ncc1)cnc1Cl)c1NS(N(C)C)(=O)=O PIVHURGZHDITTH-UHFFFAOYSA-N 0.000 description 1
- RGLGDJCAZVHWQC-ZYKWQNGHSA-N Cc(c(C(N(C)[C@H]1C(C2)CC2CC1)=O)c1)ncc1-c1ccnc(NC(C2CC2)=O)c1 Chemical compound Cc(c(C(N(C)[C@H]1C(C2)CC2CC1)=O)c1)ncc1-c1ccnc(NC(C2CC2)=O)c1 RGLGDJCAZVHWQC-ZYKWQNGHSA-N 0.000 description 1
- YZQBWQOBFKPFMF-UHFFFAOYSA-N Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1cc(Nc2nc(C3CC3)nc(C)n2)ncc1 Chemical compound Cc(c(NS(c(ccc(F)c1)c1F)(=O)=O)c1)ncc1-c1cc(Nc2nc(C3CC3)nc(C)n2)ncc1 YZQBWQOBFKPFMF-UHFFFAOYSA-N 0.000 description 1
- MOLGUBGNGUHFIU-UHFFFAOYSA-N Cc1nccc(Nc2nccc(-c3c[n]4nccc4c(NS(c(c(F)c4)ccc4F)(=O)=O)c3)c2)n1 Chemical compound Cc1nccc(Nc2nccc(-c3c[n]4nccc4c(NS(c(c(F)c4)ccc4F)(=O)=O)c3)c2)n1 MOLGUBGNGUHFIU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927055P | 2014-01-14 | 2014-01-14 | |
| US61/927,055 | 2014-01-14 | ||
| US201462054742P | 2014-09-24 | 2014-09-24 | |
| US62/054,742 | 2014-09-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201613865A TW201613865A (en) | 2016-04-16 |
| TWI662024B true TWI662024B (zh) | 2019-06-11 |
Family
ID=53543363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104101242A TWI662024B (zh) | 2014-01-14 | 2015-01-14 | 雜芳基化合物及其用途 |
Country Status (26)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104230922B (zh) | 2013-06-19 | 2016-12-28 | 中国科学院上海药物研究所 | 一类五元杂环并吡啶类化合物及其制备方法和用途 |
| MY182908A (en) | 2014-01-14 | 2021-02-05 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| SG10201912959QA (en) | 2015-10-21 | 2020-02-27 | Otsuka Pharma Co Ltd | Benzolactam compounds as protein kinase inhibitors |
| AU2017219847B2 (en) | 2016-02-19 | 2021-02-04 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
| CN108698996B (zh) | 2016-02-19 | 2021-10-01 | 思普瑞特生物科学公司 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
| WO2018144791A1 (en) * | 2017-02-03 | 2018-08-09 | Millennium Pharmaceuticals, Inc. | Combination of vps34 inhibitors and mtor inhibitors |
| GB201706327D0 (en) * | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| AU2018320419B2 (en) | 2017-08-23 | 2023-09-28 | Sprint Bioscience Ab | Morpholinylpyridone compounds |
| IL292488B2 (en) * | 2017-08-23 | 2023-09-01 | Sprint Bioscience Ab | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds |
| LT3672941T (lt) | 2017-08-23 | 2022-07-11 | Sprint Bioscience Ab | Piridilpiridono junginiai |
| SMT202100718T1 (it) | 2017-08-23 | 2022-03-21 | Sprint Bioscience Ab | Composti azaindolilpiridonici e diazaindolilpiridonici |
| BR112020004441B1 (pt) | 2017-09-18 | 2024-01-16 | Basf Se | Compostos da fórmula i, composição agroquímica, semente revestida, uso de compostos e método não-terapêutico de combate de fungos |
| CN118084940A (zh) | 2018-02-13 | 2024-05-28 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020045941A1 (ko) * | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| CN114786673A (zh) * | 2019-09-11 | 2022-07-22 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
| CN112574207B (zh) * | 2019-09-30 | 2023-04-11 | 南京药石科技股份有限公司 | Erk1/2蛋白激酶抑制剂及其用途 |
| US20230139111A1 (en) * | 2020-02-13 | 2023-05-04 | Genfleet Therapeutics (Shanghai) Inc. | Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof |
| US11801238B2 (en) | 2020-11-25 | 2023-10-31 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| AU2022405116A1 (en) | 2021-12-09 | 2024-07-11 | Deciphera Pharmaceuticals, Llc | Raf kinase inhibitors and methods of use thereof |
| AU2023364628A1 (en) | 2022-10-18 | 2025-04-03 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102471310A (zh) * | 2009-09-04 | 2012-05-23 | 诺瓦提斯公司 | 用于治疗增生性疾病的联吡啶化合物 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172460A1 (en) | 2002-11-01 | 2010-04-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| GB0425026D0 (en) * | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
| KR20070095952A (ko) | 2004-12-16 | 2007-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Ｔｅｃ 계열 단백질 키나제의 억제제로서 유용한피리드-2-온 |
| CN101111479A (zh) * | 2004-12-16 | 2008-01-23 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的吡啶酮 |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2007135398A1 (en) | 2006-05-22 | 2007-11-29 | Astrazeneca Ab | Indole derivatives |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| JP2010511682A (ja) | 2006-12-04 | 2010-04-15 | アストラゼネカ アクチボラグ | 抗菌性の多環系尿素化合物 |
| EA200900799A1 (ru) | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| KR20100025006A (ko) | 2007-07-26 | 2010-03-08 | 노파르티스 아게 | 염증성 또는 알레르기성 질병의 치료에 유용한 피리미딘 유도체 |
| WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
| WO2009039140A1 (en) | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
| EP2211615A4 (en) * | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| NZ590887A (en) | 2008-08-04 | 2012-09-28 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CA2743242A1 (en) | 2008-11-11 | 2010-05-20 | Eli Lilly And Company | P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| WO2010057877A1 (en) * | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| US8071605B2 (en) | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
| KR20120034666A (ko) | 2009-05-22 | 2012-04-12 | 엑셀리시스, 인코포레이티드 | 증식성 질환에 대한 벤족사제핀 기반 ｐ１３ｋ／ｍｔ０ｒ의 억제제 |
| CN102471339A (zh) | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| JP2011033670A (ja) * | 2009-07-30 | 2011-02-17 | Sony Corp | 光学ファインダユニットおよび撮像装置 |
| JP5675850B2 (ja) * | 2010-02-05 | 2015-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヘタリール−［１，８］ナフチリジン誘導体 |
| CA2804285C (en) * | 2010-07-05 | 2019-05-14 | Merck Patent Gmbh | Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| WO2012009227A1 (en) | 2010-07-16 | 2012-01-19 | N30 Pharmaceuticals, Llc | Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
| US8916553B2 (en) | 2010-07-26 | 2014-12-23 | Bristol-Myers Squibb Company | Sulfonamide compounds useful as CYP17 inhibitors |
| EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| EP2603214A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| US8478700B2 (en) | 2010-08-11 | 2013-07-02 | Brightedge Technologies, Inc. | Opportunity identification and forecasting for search engine optimization |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| BR112013012380A2 (pt) * | 2010-11-17 | 2016-08-30 | Novartis Ag | compostos 3-(aminoaril)-piridina |
| MX2013007336A (es) * | 2010-12-21 | 2013-08-01 | Novartis Ag | Compuestos de bi-heteroarilo como inhibidores de vps34. |
| PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US20130303507A1 (en) | 2011-01-28 | 2013-11-14 | Novartis Ag | Substituted hetero-biaryl compounds and their uses |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| DE102011077104A1 (de) | 2011-06-07 | 2012-12-13 | Siemens Aktiengesellschaft | Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom |
| KR101502500B1 (ko) | 2011-07-01 | 2015-03-16 | 주식회사 엘지화학 | 비수 전해액 및 이를 이용한 리튬 이차전지 |
| UA111382C2 (uk) * | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
| EP2793879A4 (en) | 2011-12-23 | 2015-07-01 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| BR112014020773A2 (pt) | 2012-02-22 | 2020-10-27 | Sanford-Burnham Medical Research Institute | compostos de sulfonamida e seus usos como inibidores tnap |
| EP2855472B1 (en) * | 2012-04-05 | 2016-09-14 | Boehringer Ingelheim International GmbH | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| WO2014053533A1 (en) * | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
| EP2903613B1 (en) * | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
| WO2014083327A1 (en) | 2012-11-27 | 2014-06-05 | Md Pharma Ab | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy |
| GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
| BR112015016580A2 (pt) * | 2013-01-11 | 2017-07-11 | Fujifilm Corp | composto heterocíclico contendo nitrogênio ou sal deste |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| MY182908A (en) | 2014-01-14 | 2021-02-05 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| US10167279B2 (en) * | 2014-09-12 | 2019-01-01 | Novartis Ag | Compounds and compositions as RAF kinase inhibitors |
-
2015
- 2015-01-13 MY MYPI2016702312A patent/MY182908A/en unknown
- 2015-01-13 CA CA2935867A patent/CA2935867C/en active Active
- 2015-01-13 CN CN201580004591.2A patent/CN105916503B/zh active Active
- 2015-01-13 PE PE2016001225A patent/PE20161313A1/es unknown
- 2015-01-13 AP AP2016009368A patent/AP2016009368A0/en unknown
- 2015-01-13 KR KR1020167022343A patent/KR20160122736A/ko not_active Withdrawn
- 2015-01-13 SG SG11201604820XA patent/SG11201604820XA/en unknown
- 2015-01-13 JP JP2016546472A patent/JP6609258B2/ja active Active
- 2015-01-13 ES ES15737173T patent/ES2908042T3/es active Active
- 2015-01-13 TN TN2016000270A patent/TN2016000270A1/en unknown
- 2015-01-13 EA EA201691421A patent/EA032458B1/ru not_active IP Right Cessation
- 2015-01-13 EP EP15737173.3A patent/EP3094325B1/en active Active
- 2015-01-13 WO PCT/US2015/011191 patent/WO2015108861A1/en not_active Ceased
- 2015-01-13 GE GEAP201514237A patent/GEP20196983B/en unknown
- 2015-01-13 AU AU2015206652A patent/AU2015206652A1/en not_active Abandoned
- 2015-01-13 CR CR20160363A patent/CR20160363A/es unknown
- 2015-01-13 MX MX2016009135A patent/MX2016009135A/es unknown
- 2015-01-13 BR BR112016016289-7A patent/BR112016016289B1/pt active IP Right Grant
- 2015-01-13 US US14/596,052 patent/US9802960B2/en active Active
- 2015-01-14 TW TW104101242A patent/TWI662024B/zh not_active IP Right Cessation
- 2015-01-14 UY UY0001035951A patent/UY35951A/es not_active Application Discontinuation
-
2016
- 2016-07-12 DO DO2016000173A patent/DOP2016000173A/es unknown
- 2016-07-13 PH PH12016501388A patent/PH12016501388A1/en unknown
- 2016-07-13 IL IL246755A patent/IL246755A0/en unknown
- 2016-07-14 CL CL2016001805A patent/CL2016001805A1/es unknown
- 2016-08-11 EC ECIEPI201667303A patent/ECSP16067303A/es unknown
- 2016-11-09 US US15/347,334 patent/US9751854B2/en active Active
-
2017
- 2017-08-01 US US15/665,506 patent/US10538533B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102471310A (zh) * | 2009-09-04 | 2012-05-23 | 诺瓦提斯公司 | 用于治疗增生性疾病的联吡啶化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI662024B (zh) | 雜芳基化合物及其用途 | |
| CN103313976B (zh) | sGC刺激物 | |
| CN103596952B (zh) | 作为Syk抑制剂的新型取代的吡啶并吡嗪类化合物 | |
| CN102459187B (zh) | Janus激酶抑制化合物和方法 | |
| JP2019147833A (ja) | Ｄｎａ−ｐｋ阻害剤 | |
| TW201625578A (zh) | 喹啉化合物及其用途 | |
| CN102770426B (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
| CN102695417A (zh) | 用于激酶调节的化合物和方法及其适应症 | |
| PL216368B1 (pl) | Związki aminoheteroarylowe oraz ich zastosowanie | |
| JP2023520759A (ja) | がん治療のための置換オキソイソインドリン化合物 | |
| WO2013130855A1 (en) | Indazole derivatives | |
| TW201602103A (zh) | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 | |
| TW201217362A (en) | Heteroaryls and uses thereof | |
| TWI818424B (zh) | 含氮多環稠環類化合物，其藥物組合物、製備方法和用途 | |
| CN104812755B (zh) | 作为ttx‑s阻断剂的吡唑并吡啶衍生物 | |
| WO2020215998A1 (zh) | 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途 | |
| TWI785101B (zh) | 氮雜吲哚基吡啶酮及二氮雜吲哚基吡啶酮化合物 | |
| HK1227295A1 (en) | Heteroaryls and uses thereof | |
| WO2025113625A1 (zh) | 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用 | |
| HK40034453B (zh) | 嘧啶环己烯基糖皮质激素受体调节剂 | |
| HK1190143B (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| TW201433567A (zh) | 吲唑衍生物 | |
| HK1235056B (zh) | Sgc刺激物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |